Outcome of COVID-19 in Patients withMyasthenia May Not Only Depend on the Immunologic Disease

Authors

  • Josef Finsterer, MD, PhD Klinik Landstrasse, Messerli Institute, Vienna, Austria Author
  • Carla A. Scorza Disciplina de Neurociencia, Escola Paulista de Medicina/Universidade Federal de São Paulo/. (EPM/UNIFESP). São Paulo, Brasil Author
  • Fulvio A. Scorza, MD Disciplina de Neurociencia, Escola Paulista de Medicina/Universidade Federal de Sao Paulo/. (EPM/UNIFESP). São Paulo, Brasil Author
  • Ana C Fiorini, MD Programa de Estudos Pos-Graduado em Fonoaudiologia, Pontifícia Universidade Catolica de Sao Paulo (PUC-SP). Departamento de Fonoaudiologia. Escola Paulista de Medicina/Universidade Federal de Sao Paulo (EPM/UNIFESP). São Paulo, Brasil Author

DOI:

https://doi.org/10.47310/iarjmsr.2020.V01i02.04

Keywords:

myasthenia, COVID-19, SARS-CoV-2, neuromuscular transmission.

Abstract

With interest we read the article by Camelo-Filho et al., (2020) about 15 patients with myasthenia gravis (MG) admitted to four hospitals in Sao Paolo because of an infection with SARS-CoV-2 (COVID-19). The authors found that most MG patients developed a severe course of COVID-19, such that 87% of the MG patients required transfer to the intensive care unit (ICU), that 73% required artificial ventilation, and that 30% of these patients died. We have the following comments and concerns.

Downloads

Published

2020-10-30

How to Cite

Josef Finsterer, MD, PhD, Carla A. Scorza, Fulvio A. Scorza, MD, & Ana C Fiorini, MD. (2020). Outcome of COVID-19 in Patients withMyasthenia May Not Only Depend on the Immunologic Disease. IAR Journal of Medicine and Surgery Research, 1(2), 11-12. https://doi.org/10.47310/iarjmsr.2020.V01i02.04

Similar Articles

21-30 of 30

You may also start an advanced similarity search for this article.